DNA Mismatch Repair System Imbalances in Breast Adenocarcinoma
- PMID: 36875308
- PMCID: PMC9949550
- DOI: 10.21873/cdp.10197
DNA Mismatch Repair System Imbalances in Breast Adenocarcinoma
Abstract
DNA mismatch repair system (MMR) is considered a leading genetic mechanism in stabilizing DNA structure and maintaining its function. DNA MMR is a highly conserved system in bacteria, prokaryotic, and eukaryotic cells, and provides the highest protection to DNA by repairing micro-structural alterations. DNA MMR proteins are involved in the detection and repair of intra-nucleotide base-to-base errors inside the complementary DNA strand recognizing the recently synthesized strand from the parental template. During DNA replication, a spectrum of errors including base insertion, deletion, and miss-incorporation negatively affect the molecule's structure and its functional stability. A broad spectrum of genomic alterations such as promoter hyper methylation, mutation, and loss of heterozygosity (LOH) in MMR genes including predominantly hMLH1, hMSH2, hMSH3, hMSH6, hPMS1, and hPMS2 lead to their loss of base-to-base error repairing procedure. Microsatellite instability (MSI) refers to the DNA MMR gene alterations that are observed in a variety of malignancies of different histological origins. In the current review, we present the role of DNA MMR deficiency in breast adenocarcinoma, a leading cancer-based cause of death in females worldwide.
Keywords: Breast; MMR; adenocarcinoma; epigenetics; methylation; review.
Copyright 2023, International Institute of Anticancer Research.
Conflict of interest statement
The Authors have no conflicts of interest to declare in relation to this study.
Similar articles
-
DNA mismatch repair deficiency in lung and oral cavity carcinomas: the role of histogenetic origin.J BUON. 2017 May-Jun;22(3):606-609. J BUON. 2017. PMID: 28730763 Review.
-
Alterations of DNA mismatch repair proteins and microsatellite instability levels in gastric cancer cell lines.Lab Invest. 2004 Jul;84(7):915-22. doi: 10.1038/labinvest.3700117. Lab Invest. 2004. PMID: 15133479
-
Allelic imbalance at the DNA mismatch repair loci, hMSH2, hMLH1, hPMS1, hPMS2 and hMSH3, in squamous cell carcinoma of the head and neck.Oral Oncol. 2003 Feb;39(2):115-29. doi: 10.1016/s1368-8375(02)00028-3. Oral Oncol. 2003. PMID: 12509964
-
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma.Cancer. 2003 Nov 15;98(10):2199-206. doi: 10.1002/cncr.11770. Cancer. 2003. PMID: 14601090
-
Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC).Cancer Invest. 2002;20(1):102-9. doi: 10.1081/cnv-120000371. Cancer Invest. 2002. PMID: 11852992 Review.
Cited by
-
DNA Methylation-Based Diagnosis and Treatment of Breast Cancer.Curr Cancer Drug Targets. 2025;25(1):26-37. doi: 10.2174/0115680096278978240204162353. Curr Cancer Drug Targets. 2025. PMID: 38441008 Review.
-
Molecular Basis of Breast Tumor Heterogeneity.Adv Exp Med Biol. 2025;1464:237-257. doi: 10.1007/978-3-031-70875-6_13. Adv Exp Med Biol. 2025. PMID: 39821029 Review.
-
Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application.Clin Transl Med. 2024 Nov;14(11):e70066. doi: 10.1002/ctm2.70066. Clin Transl Med. 2024. PMID: 39462685 Free PMC article. Review.
References
-
- Tasli F, Cavdar D, Kececi SD, Zengel B, Adibelli ZH, Dal G, Gonen I, Oz O, Yilmaz C, Ozdemir O, Mollamehmetoglu H, Dilek I, Ilhan E, Uslu A. The importance of the pathological perspective in the management of the invasive lobular carcinoma. Breast J. 2022;2022:2461242. doi: 10.1155/2022/2461242. - DOI - PMC - PubMed
-
- Shao C, Wan J, Lam FC, Tang H, Marley AR, Song Y, Miller C, Brown M, Han J, Adeboyeje G. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies. Environ Mol Mutagen. 2022;63(6):308–316. doi: 10.1002/em.22505. - DOI - PubMed
-
- Whitworth PW, Beitsch PD, Murray MK, Richards PD, Mislowsky A, Dul CL, Pellicane JV, Baron PL, Rahman RL, Lee LA, Dupree BB, Kelemen PR, Ashikari AY, Budway RJ, Lopez-Penalver C, Dooley W, Wang S, Dauer P, Menicucci AR, Yoder EB, Finn C, Blumencranz LE, Audeh W. Genomic classification of HER2-positive patients with 80-gene and 70-gene signatures identifies diversity in clinical outcomes with HER2-targeted neoadjuvant therapy. JCO Precis Oncol. 2022;6:e2200197. doi: 10.1200/PO.22.00197. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials